The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Respiratory Review

• Publication date

  2010-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1183/09059180.00005110PMID 20956191PMCID PMC9487283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular Predictors of Outcome with Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer:Data from the Randomized Phase III INTEREST Trial

  2011cited by this paper
• Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

  2011cited by this paper
• Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• F1000 highlights

  2010cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond

  2010cited by this paper
• Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

  2010cited by this paper
• 9003 Response and progression-free survival in 1006 patients with known EGFR mutation status in phase III randomized trials of gefitinib in individuals with non-small cell lung cancer

  2009cited by this paper
• Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS).

  2009cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Detecting an overall survival benefit that is derived from progression-free survival.

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.

  2008cited by this paper
• Oncogene addiction.

  2008cited by this paper
• Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

  2008cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

  2008cited by this paper
• Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

  2007cited by this paper
• Pilot phase II study of preoperative gefitinib in early stage non-small cell lung cancer with assessment of intratumor gefitinib levels and tumor target modulation

  2007cited by this paper
• Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST): PRS-02

  2007cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

  2006cited by this paper
• Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

  2006cited by this paper
• Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

  2005cited by this paper
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  2005cited by this paper
• Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

  2005cited by this paper
• Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

  2005cited by this paper
• The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.

  2005cited by this paper
• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005cited by this paper
• Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

  2004cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004cited by this paper
• Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.

  2004cited by this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  2004cited by this paper
• Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Development of the Novel Biologically Targeted Anticancer Agent Gefitinib

  2004cited by this paper
• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

  2003cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone

  2003cited by this paper
• Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.

  2002cited by this paper
• ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

  2002cited by this paper
• Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

  2002cited by this paper
• ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

  2002cited by this paper
• Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

  2002cited by this paper
• Globocan 2000 : cancer incidence, mortality and prevalence worldwide

  2001cited by this paper
• The epidermal growth factor receptor and its inhibition in cancer therapy.

  1999cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

  1995cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

  1995cited by this paper
• Cancer statistics

  1989cited by this paper

• Bioinformatics models in drug delivery: Predicting biomaterial-biological interactions for targeted therapies

  2026cites this paper
• An integrative machine learning approach identifies the centrality of ferroptosis, cuproptosis, and immune pathway crosstalk for breast cancer stratification and therapy guidance

  2025cites this paper
• Exploring 1,3,4-Oxadiazole-Chalcone Hybrids as Dual EGFR-Resistant Mutant Inhibitors and Antioxidants through In-Silico and Synthetic Approaches

  2025cites this paper
• Quantitative Glycan-Protein Cross-Linking Mass Spectrometry Using Enrichable Linkers Reveals Extensive Glycan-Mediated Protein Interaction Networks

  2025cites this paper
• Polimorfisme Gen Cyp2d6 Pada Efektivitas Gefitinib Terhadap Pasien NSCLC

  2024cites this paper
• Revolutionizing Cancer Treatment: Harnessing the Power of Biomarkers to Improve Patient Outcomes

  2023cites this paper
• Development of Gefitinib-Loaded Solid Lipid Nanoparticles for the Treatment of Breast Cancer: Physicochemical Evaluation, Stability, and Anticancer Activity in Breast Cancer (MCF-7) Cells

  2023cites this paper
• Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer

  2021cites this paper
• Promoting Inclusion of Members of Racial and Ethnic Minority Groups in Cancer Drug Development.

  2021cites this paper
• Artificial intelligence, molecular subtyping, biomarkers, and precision oncology

  2021cites this paper
• Delivery of gefitinib in synergism with thymoquinone via transferrin-conjugated nanoparticle sensitizes gefitinib-resistant non-small cell lung carcinoma to control metastasis and stemness.

  2021cites this paper
• A Review: Discovering 1,3,4-oxadiazole and chalcone nucleus for cytotoxicity/EGFR inhibitory anticancer activity.

  2021cites this paper
• Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer.

  2020cites this paper
• Single-Molecule Super-Resolution Microscopy Reveals Heteromeric Complexes of MET and EGFR upon Ligand Activation

  2020cites this paper
• Oral Manifestations of Nutritional Deficiencies: Single Centre Analysis.

  2020cites this paper
• Metachronous Isolated Contralateral Lung Metastasis from Pulmonary Adenosquamous Carcinoma with EGFR Mutation.

  2020cites this paper
• Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases

  2020cites this paper
• Engineering Biocompatible Heterotypic Hydrogels on Cell Surfaces

  2019cites this paper
• Esophageal Cancer: Should Gender Be Considered as an Influential Factor for Patient Safety in Drug Treatment?

  2019cites this paper
• Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identification

  2019cites this paper
• Molecular genetic and epigenetic analysis of osteoarthritis

  2017cites this paper
• Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer

  2017cites this paper
• The role of adipose secreted cytokines in driving the pathological changes in osteoarthritis

  2017cites this paper
• Personalised Medicine with Companion Diagnostics: The Intercept of Medicines and Medical Devices in the Regulatory Landscape

  2017cites this paper
• The aqueous extract of Brucea javanica suppresses cell growth and alleviates tumorigenesis of human lung cancer cells by targeting mutated epidermal growth factor receptor

  2016cites this paper
• Developing anti-inflammatory therapeutics for patients with osteoarthritis

  2016cites this paper
• Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation

  2016cites this paper
• Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib

  2016cites this paper
• Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine

  2015cites this paper
• Cancer Metabolism: Strategic Diversion from Targeting Cancer Drivers to Targeting Cancer Suppliers

  2015cites this paper
• The hallmarks of osteoarthritis and the potential to develop personalised disease-modifying pharmacological therapeutics.

  2014cites this paper
• Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.

  2014cites this paper
• Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer

  2014cites this paper
• The future of clinical research in oncology: where are we heading to?

  2013cites this paper
• Pharmacogenomics in early-phase clinical development.

  2013cites this paper
• Non-small cell lung cancer--genetic predictors.

  2013cites this paper
• Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib

  2013cites this paper
• Application of Genomic Technologies for Bridging Strategy Involving Different Race and Ethnicity in Pharmacogenomics Clinical Trials

  2012cites this paper
• Effects of voltage-gated K+ channel blockers in gefitinib-resistant H460 non-small cell lung cancer cells.

  2012cites this paper
• Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?

  2012cites this paper
• Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives

  2011cites this paper
• The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor.

  2011cites this paper
• The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.

  2011cites this paper
• Ligand-dependent differences in estrogen receptor beta-interacting proteins identified in lung adenocarcinoma cells corresponds to estrogenic responses

  2011cites this paper
• Update on the European Respiratory Review

  2010cites this paper